Tiffany Shih

Senior Manager


  • Los Angeles


Tiffany Shih consults on life sciences and healthcare litigation and regulatory investigations. Dr. Shih works with academic experts and attorneys and leads large teams to perform complex economic analyses on antitrust, product misrepresentation, reimbursement, and breach of contract matters in these industries.

Dr. Shih’s experience includes:

Antitrust litigation and merger investigations
Product misrepresentation and product liability matters
  • Assessing the impact of pharmaceutical marketing on prescribers’ behavior and prescription drug sales
  • Analyzing pharmaceutical companies’ drug development decisions
  • Examining damages in consumer personal injury matters
  • Analyzing consumer class certification issues in product liability matters in the pharmaceutical industry
Reimbursement disputes
  • Evaluating economic issues related to risk-adjusted payments to Medicare Advantage insurers
Contract disputes
  • Addressing breach of contract issues related to pharmaceutical R&D and licensing agreements

Dr. Shih has published articles on healthcare and life sciences topics in medical and economics journals. In her research, Dr. Shih has addressed how money flows through the pharmaceutical distribution system, the economic impacts of biologic drugs policies, and the economic costs of disease.

Prior to joining Cornerstone Research, Dr. Shih worked at Precision Health Economics, where she provided business consulting services to major pharmaceutical companies.


In re Novartis and Par Antitrust Litigation


United States et al. v. UnitedHealth Group Incorporated et al.


Cigna’s Acquisition of Express Scripts

  • “Short-term Costs of Preeclampsia to the United States Health Care System,” with W. Stevens, D. Incerti, T. Ton, H. Lee, D. Peneva, G. Macones, B. Sibai, and A. Jena, American Journal of Obstetrics and Gynecology 3, 2017.
  • “The Flow of Money Through the Pharmaceutical Distribution System,” with N. Sood, K. Van Nuys, and D. Goldman, Schaeffer Center White Paper Series, 2017.
  • “Product Safety Spillovers and Market Viability for Biologic Drugs,” with J. Romley, International Journal of Health Economics and Management 17: 2, 2017.
  • “Incremental Net Monetary Benefit of Ocrelizumab Relative to Subcutaneous Interferon b-1a,” with M. Frasco, D. Incerti, O. Diaz Espinosa, D. Vania, and N. Thomas, Journal of Medical Economics 20: 10, 2017.
  • “Reconsidering the Economic Value of Multiple Sclerosis Therapies,” with C. Wakeford, D. Meletiche, J. Sussell, A. Chung, Y. Liu, J. Shim, and D. Lakdawalla, American Journal of Managed Care 22: 11, 2016.
  • “The Rising Burden of Preeclampsia in the United States Impacts Both Maternal and Child Health,” with D. Peneva, X. Xu, A. Sutton, E. Triche, R. Ehrenkranz, M. Paidas, and W. Stevens, American Journal of Perinatology 33: 4, 2016.
  • Podcast and Panel: “Big (Bad?) Data and the Healthcare Consumer,” 24th Annual Emerging Issues in Healthcare Law Conference, 10 March 2023